Posted by Michael Wonder on 25 May 2023
FORUS Therapeutics and the Pan-Canadian Pharmaceutical Alliance complete negotiations for Xpovio (selinexor)
24 May 2023 - The pCPA agreement will support the public listings and reimbursement of Xpovio.
FORUS Therapeutics and the pan-Canadian Pharmaceutical Alliance have completed negotiations with a letter of intent for Xpovio (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
